In
vitro maturation in polycystic ovary Syndrome and poor
responders. Effect of follicular size and FSH concentration
in culture media
..........................................................................................................................
Dr
Yousif Elbarbary
Medical Officer. Almana General
Hospital, Alkhobar, Saudi Arabia
Dr Mahmoud Samy
Associate Professor. Benjamin Franklin, Charité,
Homboldt University, Germany Dr Hythum Y Ibrahim
Consultant Obstetricians and Gynaecologist. Heartlands
Hospital, Birmingham, UK
..........................................................................................................................
|
ABSTRACT
Objectives:
- To
determine the effect of recombinant Follicle
Stimulating Hormone (r-FSH) concentration in
culture media on in vitro maturation outcomes.
- To
determine the effect of the follicle size on
in vitro maturation outcomes.
- To
determine the in vitro maturation outcomes of
immature oocytes recovered from infertile patients
with polycystic ovaries (PCO) and poor responders.
Design
& Methods: Two-stage prospective study
was performed in an IVF unit in the eastern province
of Saudi Arabia. The first stage compared the
fertilization and pregnancy outcomes in patients
with Polycystic Ovary (PCO) Syndrome and patients
with poor response to recombinant Follicular Stimulation
Hormone (rFSH). The second compared these outcomes
according to follicular size.
Oocytes
retrieved after 5 days rFSH course were divided
into two groups according to follicular size (8-10mm
and 11-13mm) and were cultured in a 0.075 IU/ml
medium.. The effect of follicular size on oocytes-maturation,
fertilization, embryo cleavage, and pregnancy
rate was assessed in the two groups and in those
with PCO and poor responders.
Results:
There was no difference in the main outcome measures
between oocytes cultured in the two concentrations
of FSH. Oocytes retrieved from 11-13 mm follicles
showed higher rates of maturation, fertilization
and pregnancy, than those retrieved from 8-10
mm follicles. In both PCO and poor responders
patients embryos produced from regularly cycling
patients had a significantly higher embryo development
ratio, even though cleavage was not significantly
different.
Conclusion:
Concentrations higher than 0.075 IU ml in culture
media for IVM are not necessarily associated with
better outcomes. Larger follicular size produces
better fertilization and pregnancy rates. In both
PCO and poor responders, cycle irregularity is
associated with poorer outcomes.
|
Since the
first successful human pregnancy from in-vitro fertilization
(IVF) was achieved (Steptoe and Edwards, 1978), assisted
reproductive technology has become the frontier of birth
infertility treatment and research. There have been
continuous improvements in the pregnancy and birth rates
with IVF.
These improvements have been directly
attributed to advances in the hormonal stimulation of
patients with various controlled ovarian hyperstimulation
(COH) protocols and improved culture media and culture
systems for oocytes, sperm, and embryos. However, through
all these improvements with stimulated cycles, there
has been continued development with natural, unstimulated,
or limited-stimulation cycles followed by in vitro maturation
(IVM) of oocytes. Any protocol that would decrease the
amount and duration of hormonal stimulation before oocyte
retrieval would have an advantage over the more common
COH/IVF protocols if the resulting pregnancy rates were
the same or improved (Cha K. et al, 1991). Research
in in-vitro maturation (IVM) of the human oocyte has
shown significant progress and provided hope for certain
groups of patients who have either poor response or
have a high risk of developing ovarian hyperstimulation.
Human oocytes recovered from immature follicles, following
retrieval can resume and complete meiosis in-vitro when
cultured in media supplemented with recombinant follicle
Stimulating Hormone (r-FSH) and Human Chorionic Gonadotrophin
(hCG) (Trounson A., et al, 2001; Hreinsson J. et al,
2003; Lin Y. et al, 2003).
Several reports showed that in-vitro
matured oocytes could be fertilized, and result in pregnancy
(Jaroudi K., et al, 1999), and birth of healthy babies
(Chian R., et al, 2001, Suikkari A. et al, 2005). Despite
the clinical utilization of IVM in the field of human
reproduction, its pregnancy and birth rates remain low
compared to in-vivo matured oocytes (Lui J., et al,
2003, Lin Y.,et al, 2003).
This study
aims to study the effect of the follicles' size on oocyte
maturation, fertilization and cleavage, and to compare
the outcomes of in-vitro maturation of immature oocytes
recovered in situ from infertile women with polycystic
ovaries, versus poor responders.
- To determine the effect of recombinant
follicle stimulating hormone (r-FSH) concentration
in culture media on in vitro maturation outcomes.
- To determine the effect of the
follicle size on in vitro maturation outcomes.
- To determine the in vitro maturation
outcomes of immature oocytes recovered from infertile
patients with polycystic ovaries (PCO) and poor responders.
This study was conducted during the
period from April 2000 to December 2004. The results
of this study were collected and evaluated from the
Assisted Reproduction Unit at Almana General Hospital,
Dammam, Eastern Province of the Kingdom of Saudi Arabia
and incorporation with the department of Obstetrics
and Gynecology, Campus Benjamin Franklin, Charité,
Homboldt University. The study was approved by the research
ethics board of the hospital. A written informed consent
was obtained from all patients. To decide which concentration
to use in the culture medium, a preliminary experiment
was performed to compare 2 concentrations (7.5 IU/ml
and 0.075 IU/ml) and compared to a medium with no FSH.
(A) The effect of r-FSH concentration
in the culture media on in-vitro maturation of oocytes
Recombinant FSH in the culture media
was used in two concentrations of 0.075, 7.5 IU/ml and
none as a control.
This experiment was performed on
patients producing more than 15 germinal vesicles (GV)
oocytes. Immediately after collection, the oocytes were
equally distributed in three groups of 5 oocytes each
in three center-well dishes containing 3ml Ham's F10
media.
Two r-FSH concentrations of 0.075,
7.5 IU/ml were added in two dishes and none as control,
respectively. Oocytes maturation was evaluated 30 hours
after incubation. Oocytes maturation, fertilization,
cleavage and pregnancy rates were assessed.
(B) The effect of follicular size
on the rate of oocyte maturation
In this experiment, oocytes were
collected from 50 PCO patients (Group 2) who were stimulated
with a daily dose of 300 IU (Purgeon, Organon, Holland)
for 5 days, starting on day 2 of the menstrual cycle
until day 6 when a transvaginal ultrasound scan was
performed. The scan showed follicular size ranging between
8-13 mm. The PCO patients were divided into two subgroups
according to follicular size on the day of hCG injection;
Group 2I had a follicular size of 8-10 mm and Group
2II had a size of 11-13 mm. The oocytes retrieved from
these patients were incubated for 30 hours in Ham's
F10 supplemented with 0.075 IU r-FSH/ml. Oocyte maturation,
fertilization, cleavage, and pregnancy rates were then
assessed.
(C) In vitro maturation outcomes
of immature oocytes recovered in-situ from infertile
patients with polycystic ovaries (PCO) and poor responders
This part of the study was conducted
on 40 infertile women (Group 3). This group was further
divided into two subgroups, 20 infertile women with
polycystic ovaries (Group 3I) and 20 poor responder
infertile women (Group 3II). The timing of the start
of treatment was random, as most of the patients had
an irregular menstrual cycle.
Infertile women with polycystic ovaries
and poor responders were included in this study during
their schedule for ICSI in the IVF program. The patients
were recruited at random. It was fully explained to
each patient that the procedures related to the study
were not part of the routine diagnostic procedures required
for their infertility assessment.
Patients were recruited after PCO
was identified by:
- Pelvic ultrasound (the ultrasonic
criteria of PCO were essential for the diagnosis.
It included the presence of more than 8 small follicles
of 2-8 mm in diameter around a dense core of stroma
and a dense ovarian capsule),
- Their endocrine and clinical features
varied between regular and irregular cycles,
- Anovulatory polycystic ovarian
syndrome patients had characteristically elevated
androgen level, LH: FSH ratio >2, and frequently,
the clinical features of hirsutism and increased body
weight (Adams J. et al., 1985; Hershlag A. et al,
1996).
Poor responders are patients who
fulfilled one or more of the following criteria:
- Failed to achieve estradiol concentration
above the level of 200 pg /ml on the day of hCG (Garcia
J. et al, 1983).
- Produced less than three mature
follicles during the previous stimulation attempts
(Serafini P. et al, 1988).
- Failure and/or cancellation of
previous IVF cycles due to low quality of oocytes
retrieved in previous stimulations (Rienzi L. et al,
2002).
Oocytes retrieval and IVM Procedure
Transvaginal ultrasound guided oocytes collection was
performed using a specially designed 17-G single-lumen
aspiration needle (Casmed, UK) with a reduced aspiration
pressure of 7.5 kpa. Aspiration of the follicles was
performed under general anesthesia for all patients.
All patients received an antibiotic cover of a single
dose of 500 mg of metronidazole intravenously during
the procedure.
Oocytes were collected in culture
tubes containing warm Earl's balanced salt solution
with 5000 IU/ml heparin. Immature oocytes were incubated
in a culture dish containing 1ml of 3M (Medicult) medium
supplemented with r-FSH (Puregon, Organon) (according
to the stage of the study) and 5.00 IU/ml hCG (Pregnyl,
Organon) at a temperature of 37°C in an atmosphere
of 5% CO2 and 95% air with high humidity. After culture,
the maturity of the oocytes was determined under the
stereomicroscope at 30 hours post collection. Oocytes
were denuded of cumulus and maturity was determined
by the presence of the first polar body. Suitable oocytes
were injected with single spermatozoa by micromanipulation
(Research Instrument, UK). Following ICSI, each oocyte
was transferred into 1ml of Medi-cult IVF medium in
a tissue culture dish. Fertilization was assessed 18
hours after ICSI for the appearance of two distinct
pronuclei and two polar bodies. Oocytes with two pronuclei
were further cultured in Medi-cult IVF medium. Embryos
were transferred on day 2 or 3 after ICSI.
Statistical analysis was done
by the student's t - test. Frequency data were analyzed
by ?2 contingency tests. Embryo development ratio data
were analyzed by analysis of variance. Values were considered
significant when P<0.05. Since the oocytes were not
matured and inseminated at the same time following maturation
in culture; the development stages of embryos were variable
both within and between patients.
The results
of the present study were based on data generated from
the two experiments. The mean duration of infertility
was 12.3 ± 4.6 years for all patients of the
study groups. All patients were under 45 years of age
with a range of 21 - 44 years (mean 35.1 ± 5.3
years).
Results
of the First experiment (FSH Concentration)
The first experiment
was designed to define the optimum r-FSH concentration.
Our data showed that 0.075 IU/ml was the optimum concentration
that provided higher maturation, fertilization and pregnancy
rates compared to 7.5 IU/ml and the control. Details
regarding the number of oocytes collected, maturation,
fertilization and pregnancy rates after in vitro maturation
in media containing different concentrations of r-FSH
are shown in table 1. Recombinant
FSH concentration had significantly (p<0.05) increased
the rate of oocyte maturation from 47% at 0 concentration
to 81% and 83% at 0.075 and 7.5 IU/ml, respectively.
Fertilization, cleavage, and clinical pregnancy rates
showed a similar trend and significantly increased from
45% to 83% and 80%; from 32% to 80% and 77% and from
0% to 17% and 14% at the three concentrations, respectively.
The results however showed that increasing r-FSH concentration
to levels more than 0.075 IU did not further improve
maturation, fertilization, cleavage and pregnancy rates
even when the concentration was increased up to 100
folds. Our data showed that 0.075 IU/ml was the optimum
concentration that provided higher maturation, fertilization
and pregnancy rates compared to 7.5 IU/ml and the control.
Results
of the Second experiment (Follicular Size)
Based on the optimum
rFSH concentration as decided from the first experiment,
the second experiment was designed to study the effect
of the follicle size on oocytes maturation, fertilization
and developmental competence.
The concentration
of rFSH chosen was 0.075 IU.
The results
of two different follicle sizes (group 2) are shown
in table 2. Oocytes retrieved from
11-13 mm follicles showed higher rates of maturation,
fertilization and pregnancy, than those retrieved from
8-10 mm follicles. The above parameters increased from
48 to 70%; from 54 to 76% and from 11 to 22.5%, in the
two follicle sizes, respectively. In the first subgroup
study (group 2I), the 6 and 5 pregnancies resulting
from oocyte cultured in media containing 0.075 and 7.5
IU/ml all ended in delivery of healthy children. On
the other hand, in the second subgroup (group 2II),
the two pregnancies resulting from 8-10 mm follicles
size completed full term, whereas two of the nine pregnancies
in the 10-12 mm follicle size subgroup ended in miscarriage
and the remaining seven pregnancies ended in delivery
of healthy babies. Follicular size showed significant
(P<0.05) effect on the assessment parameters.
Results
of the Third experiment (PCO and Poor responders)
The mean age of group 3 patients was 32.3
± 5.8 for PCO patients and 36.4 ± 7.1
for the group of poor responders. The means of parity,
abortion, and Hb% were also comparable between the two
sub groups. Both the body mass index (29.7 ±
2.3 vs. 27.1 ± 1.6) and the duration of the cycles
(53.2 ± 21.3 vs. 30.3 ± 8.6) were higher
in group 3I (table 3). There was however
no difference between the two subgroups (group 3I and
group 3II) in the concentrations of estradiol, progesterone,
FSH, and LH on day 2 and on the day of oocytes retrieval
(tables 2).
From 20 PCO women (Group 3I),
the mean number of oocytes recovered, matured in vitro,
fertilized after insemination, and cleaved in culture
was 23.5, 16.1, 7.3, and 4.7 respectively.
From 12 irregular PCO women (G3Ia),
the mean numbers of oocytes recovered, matured in vitro,
and fertilized after insemination, and cleaved in culture
were 18.1, 11.7, 4.2, and 3.1, respectively. The mean
numbers of oocytes recovered, matured, fertilized and
cleaved from 8 regular cycling PCO women (G3Ib) were
5.4, 4.4, 3.1 and 1.6, respectively. Oocytes recovered
from regularly cycling patients had a higher developmental
potential when compared with irregular and anovulatory
patients with significantly (P < 0.05) including
higher maturation and fertilization rates (table
4). Cleavage was not significantly different between
the two subgroups, although there was a trend to increased
cleavage of embryos in the regular cycling group. Moreover,
embryos produced from regularly cycling patients had
a significantly higher embryo development ratio (P<
0.05), indicating the faster cleavage rate of embryos
produced from this group of patients. Embryo development
ratio is defined as the observed cleavage stage/ the
expected cleavage stage × 100. Three pregnancies
were obtained, one has delivered a pre-term at 36 weeks
and two miscarried at 8 and 10 weeks.
From 20 poor responder women (Group
3II), the mean numbers of oocytes recovered, matured
in vitro, fertilized after insemination, and cleaved
in culture were 18.1, 14.5, 5.1 and 3.4 respectively
(table 5). The embryo development
ratio was 63.4 ± 2.6. One pregnancy was obtained
with the delivery of a full term female baby.
The feasibility of obtaining full-term
pregnancies from in vitro-matured immature oocytes obtained
from stimulated and non-stimulated ovaries is well established
(Veek L. et al, 1983; Cha K. et al, 1991). The scarcity
of subsequent reports points to the fact that the procedure
is not even close to being transferred into daily clinical
work. The impossibility of judging ooplasmic maturation
forces the use of nuclear maturation as the basis for
classification of female gametes.
The present study showed that in-vitro
matured oocytes retrieved from PCOS patients had the
potential to undergo successful maturation, fertilization
and the resultant embryos and showed good developmental
competence. Following the IVM procedure, embryo transfer
culminated in clinical pregnancies and birth of healthy
children. All the oocytes retrieved in this study were
at the germinal vesicle (GV) stage. The latter is defined
as the stage that represents oocytes arrested at prophase
of meiosis-1 with prominent discernable germinal vesicle
nucleus.
There are various factors that affect
oocyte in-vitro maturation. The most important among
these factors are: the exposure of the immature oocyte
to gonadotrophins in the culture media, and the follicle
size at which the oocyte was retrieved. r-FSH, LH, and
hCG (Hreinsson J. et al, 2003), and purified gonadotrophins
(Mikkelser A.L.et al, 2001) were used to induce oocyte
maturation in vitro. In this study the effect of both
factors on oocyte maturation, fertilization, cleavage,
and pregnancy rates were investigated.
Cha et al, reported a pregnancy rate
of 27.1% after IVM and IVF-ET in patients with PCOS.
They also reported that the combined ET (ZIFT + uterine
ET) yielded a significantly higher pregnancy rate than
either ZIFT alone or uterine ET alone (Cha K., et al,
2000). Previously, other studies have shown that the
pregnancy rate of conventional IVF in PCOS patients
was similar to that of conventional IVF in non-PCOS
(MacDougall M., et al, 1993). A possible mechanism suggested
for the lower pregnancy rate of IVM is that some of
the oocytes undergoing nuclear maturation after IVM
are incapable of undergoing cytoplasmic maturation,
thus resulting in poor embryo quality and a higher incidence
of pregnancy failure. A number of other factors might
lead to a lower success rate of IVM, including sub-optimal
culture conditions, advancing maternal age, an endocrine
disturbance, previous IVF failures, and sub-optimal
timing of insemination (Picton H., 2002).
Table 6:
Compares different oocyte in-vitro maturation rates
obtained from various studies to the rate obtained in
our study.
The variations
in maturation rates between the present study and those
mentioned in table 6 may be due to
the composition of the culture medium used and protein
supplement. In the present study our optimum culture
time (30h) was comparable with other studies (Cha K.Y.
et al, 1998). Inadequacies of cultured media could not
be ruled out as a possible cause for low IVM success
(Combelles C.M. et al, 2002). There is evidence suggesting
that culture media used for IVM adequately support nuclear
maturation, but failed to produce oocyte with cytoplasmic
maturation. While we used synthetic serum supplement
as a sources of proteins, in other studies fetal bovine
serum (FBS) was used. FBS was considered more crucial
for bovine oocyte maturation than human. In addition,
our base medium used was Hams F10, which is designed
to meet the nutritional and maturational needs of human
oocyte.
On the other hand the effect of follicle
size on the above parameters showed some interesting
results. Our data showed that oocyte maturation rate
and developmental competence has significantly increased
with increase in follicle size. Eppig J.J. et al, (1992),
concluded that developmental competence of oocytes depends
on the follicle and oocyte size. The growth in size
is due to the fact that oocyte synthesizes and stores
mRNA and proteins that are essential for the completion
of maturation and for the subsequent acquisition of
embryo developmental competence (Gosden R. et al, 1995).
This probably explains the relatively higher maturation,
fertilization, cleavage, and pregnancy rate in oocyte
obtained from follicle with 11-13 mm size rather than
8-10 mm. While in the present study pregnancy rate increased
with follicle size, other reports found that implantation,
pregnancy, and birth rates were independent of follicular
size (Wittmaack F. et al, 1994; Salha O. et al, 1998).
Our data suggested that when oocytes were cultured in
IVM media containing 0.075 IU r-FSH or retrieved from
follicle size exceeding 10mm, a comparable or even better
maturation rates and developmental competence than results
shown in several recent reports were obtained.
Also, the results indicate that in
vitro maturation of oocytes recovered from PCO patients
exhibit developmental competence more than the oocytes
recovered from poor responder patients. The explanation
of this finding might be related to the age of the patients
where most of the poor responders are older than PCO
patients with the contribution of other factors like
the male factor, whereas PCO patients are younger and
their main problem was the competency of in vivo oocytes
maturation. In studying the effect of the male factor,
all males in PCO patients had normal sperm count and
viability. In poor responders, only 1 case showed subnormal
sperm count. The effect of the male factor could be
omitted in our study due to the low number of cases
and the inability of any statistical evaluation.
IVM is a useful treatment option
for women with PCOS or who are resistant to FSH with
less risk of Ovarian Hyperstimulation. As this group
of patients are resistant to gonadotropin stimulation
for various reasons and as they require prolonged and
higher doses of gonadotrophin stimulation protocols,
IVM provides a different approach to a safer and cheaper
treatment modality. In addition, natural-cycle IVF combined
with IVM might provide more efficient treatment for
poor responder infertile women.. Oocyte maturation and
embryo development are less in women with irregular
menstrual cycles.
In the present study factors affecting
immature oocyte maturation and developmental competence
are not fully explored. There are many gaps that need
to be bridged and other factors need to be closely investigated.
The effect of growth hormone in culture media during
oocyte maturation, chromosomal anomalies as well as
the effect of anesthesia is a worthwhile thorough investigation.
Table
1. The effect of
different r-FSH concentrations (in IU) on oocytes
maturation, fertilization, embryo cleavage and pregnancy
rate
|
Parameters
|
(0.00)
|
(0.075 IU)
|
(7.5 IU)
|
|
GV
collected
|
225
|
219
|
230
|
|
Matured
oocyte
|
105
(47%)
|
178
(81%)
|
186
(83%)
|
|
Fertilized
oocyte
|
47
(45%)
|
147
(83%)
|
149
(80%)
|
|
Cleaved
embryos
|
15
(3%)
|
119
(80%)
|
116
(77%)
|
|
Transferred
embryos
|
12
(2/ET)
|
55
(1.4ET)
|
60
(1.7/ET)
|
|
Clinical
Pregnancy
|
0.00
|
6
(17%)
|
5
(14%)
|
|
No
of patients who had ET
|
6
|
39
|
35
|
back
to text
Table 2.The
effect of follicular size on oocytes-maturation, fertilization,
embryo cleavage, and pregnancy rate
|
Parameters
|
Follicular
size (mm)
|
|
8-10
|
11-13
|
|
GV collected
|
250
|
250
|
|
Matured oocyte
|
120 (48%)a
|
177 (70%) b
|
|
Fertilized oocyte
|
65 (54%) a
|
138 (76%) b
|
|
Cleaved embryos
|
42 (64%) a
|
94 (68%) b
|
|
Transferred embryos
|
33 (1.9/ET)
|
60 (1.7 ET)
|
|
Clinical pregnancy
|
2 (11%) a
|
9 (22.5%) b
|
|
No of patients who had ET
|
17
|
40
|
back
to text
Table
3. Patients Criteria
|
Variable
|
G3I
|
G3II
|
P-value
|
|
Age (years)
|
32.3 ± 5.8
|
36.4 ± 7.1
|
0.496 Not Significant
|
|
Parity
|
0.63 ± 1.2
|
0.94 ± 1.8
|
0.251 Not Significant
|
|
Duration
of cycle (Days)
|
53.2 ± 21.3
|
30.3 ± 8.6
|
< 0.001 Significant
|
|
BMI
|
29.7 ±2.3
|
27.1 ± 1.6
|
0.038 Significant
|
|
Hb g%
|
13.0 ± 0.7
|
12.5 ± 1.0
|
0.126 Not Significant
|
back
to text
Table 4. Oocytes maturation,
fertilization and cleavage in vitro in study group
3 (G3)
|
Patient
group (G3)
|
Oocytes
cultured
|
Oocytes
matured
|
Oocytes
fertilized
|
Oocytes
cleaved
|
Embryo
development ratio
|
|
PCO
patients (G3I)
|
250
|
170
(68%)
|
56
(22.4%)
|
45
(18%)
|
74.2
± 2.6
|
|
Poor
responders (G3II)
|
200
|
140
(70%)
|
60
(30%)
|
35
(17.5%)
|
63.4
± 2.6
|
|
P-value
|
0.251
|
0.125
|
0.046
|
0.223
|
0.049
|
back
to text
Table
5. Oocytes maturation, fertilization and cleavage
in vitro in study group 3I (G3I)
|
Patient
group (G3I)
|
oocytes
cultured
|
oocytes
matured
|
oocytes
fertilized
|
oocytes
cleaved
|
Embryo
development ratio
|
|
Irregular
anovulatory (G3Ia) (12 patients)
|
175
|
112
(64%)
|
31
(27.9%)
|
27
(14.1%)
|
66.7
± 3.1
|
|
Regular
cycle (G3Ib) (8 patients)
|
75
|
58
(74%)
|
25
(33%)
|
18
(18%)
|
81.5
± 3.4
|
|
Total
|
250
|
170
(68%)
|
56
(22.4%)
|
45
(18%)
|
74.2
± 2.6
|
|
P-value
|
0.046
|
0.016
|
0.038
|
0.049
|
0.028
|
back
to text
Table
6: maturation rates obtained from this study compared
with other recent studies.
|
Study
|
Rate
|
|
Our
present study
|
81%
|
|
Barnes
F., et al, 1996
|
62%
|
|
Hwu
Y., et al, 1998
|
67%
|
|
Jaroudi
K. et al, 1999
|
71%
|
|
Child
T., et al, 2001
|
61%
|
|
Combelles
C., et al, 2002
|
66%
|
|
Gaspard
O., et al, 2003
|
58%
|
|
Hreinsson
J., et al, 2003
|
55.9%
|
back
to text
Appendix: Components
of culture media Nutrients Mixture Ham’s F-10
|
Old
Cat. No.
New
Cat. No.
|
041-02390
22390
IX
Liquid
|
|
Component
|
Mg/L
|
|
INORGANIC
SALTS:
|
|
|
CaCI2
(anhyd.)
CaCI2
*2 H2O
CuSO4
*5 H2O
FeSO4
*7H2O
KCI
KH2PO4
MgSO4
(anhyd.)
MgSO4
*7 H2O
NaCI
NaHCO3
Na2HPO4
(anhyd.)
ZnSO4
*7 H2O
|
-
|
|
44.00
|
|
0.0025
|
|
0.834
|
|
285.00
|
|
83.00
|
|
-
|
|
153.00
|
|
6900.00
|
|
1200.00
|
|
154.50
|
|
0.0288
|
|
OTHER
COMPONENTS:
|
|
|
D-Glucose
HEPES
Hypoxanthine
Hypoxanthine
(sodium salt)
DL-68-Thioctic
Acid
Phenol
Red
Sodium
Pyruvate
Thymidine
|
1100.00
|
|
5958.00
|
|
4.08
|
|
-
|
|
0.20
|
|
1.20
|
|
110.00
|
|
0.73
|
|
AMINO
ACIDS:
|
|
|
L-Alanine
L-Arginine
*HCI
L-Asparagine
L-Aspartic
Acid
L-Cysteine
L-Glutamic
Acid
L-Glutamine
L-Alanyl
– L-Glutamine
L-Glycine
L-Histidine
HCI * H2Ob
L-Isoleucine
L-Leucine
L-Lysine
* HCI
|
8.92
|
|
211.00
|
|
12.98
|
|
13.30
|
|
25.00
|
|
14.70
|
|
146.00
|
|
-
|
|
7.52
|
|
23.00
|
|
2.60
|
|
13.10
|
|
29.30
|
|
L-Methionine
L-Phenylalanine
L-Proline
L-Serine
L-Threonine
L-Tryptophan
L-Tyrosine
L-Tyrosine
(disodium salt)
L-Valine
|
4.48
|
|
4.96
|
|
11.50
|
|
10.50
|
|
3.58
|
|
0.60
|
|
1.81
|
|
-
|
|
3.50
|
|
VITAMINS:
|
|
|
Biotin
D-Ca
Pantothenate
Choline
Chloride
Folic
Acid
i-Inositol
Niacinamide
Pyridoxal
HCI
Riboflavin
Thiamine
HCI
Vitamin
B12
|
0.024
|
|
0.72
|
|
0.70
|
|
1.31
|
|
0.54
|
|
0.62
|
|
0.21
|
|
0.38
|
|
1.01
|
|
1.36
|
- Ware JE,
Sherbourne, CD. The MOS 36-Item Short-Form Health
Survey (SF-36): I. Conseptual framework and item selection.
Med Care 1992;30(6):473-83.]
- Bardage C, Isacson DGL. Hypertension
and health-related quality of life: an epidemiological
study in Sweden. J Clin Epidemiol. 2001 Feb;54(2):172-81.
- Paschalides C, Wearden AJ, Dunkerley
R, et al. The associations of anxiety, depression
and personal illness representations with glycaemic
control and health-related quality of life in patients
with type 2 diabetes mellitus. J Psychosom Res. 2004
Dec;57(6):557-64.
- Lalonde L, Clarke AE, Joseph
L, et. al. The Canadian Collaborative Cardiac Assessment
Group. Health-related quality of life with coronary
heart disease prevention and treatment. J Clin Epidemiol.
2001 Oct;54(10):1011-8.
- Aydemir O, Ozdemir C, Koroglu
E. The Impact of Co-morbid Conditions on the SF-36:
A Primary-care Based Study Among Hypertensives. Arch
Med Res. 2005 Mar-Apr;36(2):136-41.
- Hickson M, Frost G. An investigation
into the relationships between quality of life, nutritional
status and physical function. Clin Nutr. 2004 Apr;23(2):213-21.
- Lindsay GM, Hanlon P, Smith LN,
et. al Assessment of changes in general health status
using the short-form 36 questionnaire 1 year following
coronary artery bypass grafting. Eur J Cardiothorac
Surg. 2000 Nov;18(5):557-64.
- Hunt JO,
Hendrata MV, Myles PS. Quality of life 12 months after
coronary artery bypass graft surgery. Heart Lung.
2000 Nov-Dec;29(6):401-11.
- Welke
KF, Stevens JP, Schults WC, et. al. Patient Characteristics
Can Predict Improvement in Functional Health After
Elective Coronary Artery Bypass Grafting. Ann Thorac
Surg 2003;75:1849-55.
- Ware JE,
Kosinski M, Dewey JE. How to score Version 2 of the
SF-36 Health Survey. Lincoln, RI: QualityMetric Incorporated,
2000, 28.
- Nutritional
Disorders. In: ed(s). Beers MH, Berkow R The Merck
Manual of Diagnosis and Therapy, Whitehouse Station,
N.J. Merck Research Laboratories, 1999, 26.
- Hemingway H, Nicholson A, Stafford
M, et. al. The Impact of socio-economic status on
health functioning as assessed by the SF-36 questionnaire:
the Whitehall II study. Am J Public health 1997;87:1484-90.
- Sullivan
M, Karlsson J. The Swedish SF-36 Health Survey III.
Evaluation of criterion-based validity: results from
normative population. J Clin Epidemiol 1998;51:1105-13.
- Ragazzoni
P, Molinari E, Morosin A. satisfaction with Life,
Anxiety and Eating Attitude in a Sample of Obese Women.
Eur Neuropsychopharmacol. 1996 Jun;6(3):57.
- Hubert
HB, Snider J, Winkleby MA. Health status, health behaviors,
and acculturation factors associated with overweight
and obesity in Latinos from a community and agricultural
labor camp survey. Prev Med. 2005 Jun;40(6):642-51.
- Gupta R, Misra A, Pais P, et.
al Correlation of regional cardiovascular disease
mortality in India with lifestyle and nutritional
factors. Int J Cardiol. 2006 Apr 14;108(3):291-300.
Epub 2005 Jun 22.
- Krousel-Wood
M. Health status assessment in a hypertension section
of an internal medicine clinic. Am J Med Sci 1994;308:211-7
- Laforge
RG, Rossi JS, Prochaska JO, et. al. Stage of Regular
Exercise and Health-Related Quality of Life. Prev
Med. 1999 Apr;28(4):349-60.
- Conti
S, Masocco M, Meli P, et. al. Eating habits and lifestyles:
a multivariate analysis of the data from an Italian
population-based survey. Nutr Res 2004;24:495-507.
- Toobert
DJ, Glasgow RE, Strycker LA, et. al. Biological and
Quality-of-Life outcomes From the Mediterranean Lifestyle
Program. Diabetes Care. 2003 Aug;26(8):2288-93..
- Panagiotakos
DB, Pitsavos C, Zampelas A, et. al. Fish consumption
and risk of developing acute coronary syndromes: the
CARDIO2000 study. Int J Cardiol. 2005 Jul 20;102(3):403-9.
|